Home » Stock Symbols » BIIB

Biogen Inc.

BIIB: Share Price & Live Data

278.69 USD
-5.52 (-1.94%)
Price open 284.21
Previous close 284.21
Market cap 50.29B
Volume 703.96K
Day high 284.70
Day low 278.38
Year high 338.87
Year low 215.78

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Latest Biogen Inc. News

S&P 500 Index – An overview of Tuesday, October 22nd, 2019

Thanks to the recurrent reassurances from Trump administration that the U.S – China trade negotiations are proceeding better than expected, the S&P 500 index is having the time of its life. The breakout above the previously highlighted crucial resistance located at 3,000 level has been marked sustainable, as per the stock market analy...

S&P 500 Index – An Overview Of Monday, October 21st, 2019

Following the update from China’s top negotiator regarding the U.S – China trade talks over the weekend, the outlook for the S&P 500 index has been positive so far on Monday, October 21st, 2019. The market opened at 2,996.48 level. Three hours into the trading session, the market continues to remain above the opening level. After maki...

Overview

Name
Biogen Inc.
Exchange
NASDAQ Stock Exchange
Sector
Healthcare
Industry
Drug Manufacturers—General
Country
United States
Full time employees
7,800

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.